Agios Pharmaceuticals

AGIO Mid Cap

Healthcare · Biotechnology

Aktualisiert: Apr 5, 2026, 17:43 UTC

$35.20

+2.95% heute

52W: $22.24 – $46.00

52W Low: $22.24 Position: 54.5% 52W High: $46.00

🔗 Broker vergleichen

Kennzahlen

P/E Ratio

—

Kurs/Gewinn-Verhältnis

Forward P/E

—

Erwartetes KGV

P/S Ratio

38.17x

Kurs/Umsatz-Verhältnis

EV/EBITDA

—

Unternehmenswert/EBITDA

Dividendenrendite

—

Jährl. Dividendenrendite

Market Cap

$2.1B

Marktkapitalisierung

Umsatzwachstum

86.1%

YoY Umsatzwachstum

Gewinnmarge

—

Nettomarge

ROE

-30.2%

Eigenkapitalrendite

Beta

0.79

Marktsensitivität

Short Interest

10.64%

% der Aktien leerverkauft

Ø Volumen

929,068

Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal

N/A

vs. S&P 500 Ø KGV (24.7x)

Analysten-Konsens

Kaufen

8 Analysten

Ø Kursziel

$43.75

+24.29% Upside

Kursziel Spanne

$28.00 – $65.00

Über das Unternehmen

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenyla

Sektor: Healthcare Branche: Biotechnology Land: United States Mitarbeiter: 539 Börse: NMS

Trading-Daten

50-Day MA: $28.76

200-Day MA: $33.78

Volumen: 1,283,322

Ø Volumen: 929,068

Short Ratio: 7.95

Kurs/Buchwert: 1.72x

Verschuldung/EK: 3.37x

Free Cash Flow: $-267,967,504

Wo kann ich Agios Pharmaceuticals kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Broker vergleichen →